Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

169 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations
  • GSK Investigational Site Brussels, Belgium
  • GSK Investigational Site Fraiture En Condroz, Belgium
  • GSK Investigational Site Hamburg, Free and Hanseatic City of Hamburg, Germany
  • GSK Investigational Site Hamburg, Free and Hanseatic City of Hamburg, Germany
View Trial Details
Completed

A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Mayo Clinic Scottsdale Arizona Scottsdale, Arizona, United States
  • Clinical Trials, Inc Little Rock, Arkansas, United States
  • East Bay Physicians Medical Group Berkeley, California, United States
  • Nerve Pro Research Irvine, California, United States
View all 49 locations
View Trial Details
Completed

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

NCT00530348

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates, P.C. Cullman, Alabama, United States
  • Barrow Neurological Institute, St. Joseph's Hospital & Medical Center Phoenix, Arizona, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Northwest NeuroSpecialists, PLLC Tucson, Arizona, United States
View all 101 locations
View Trial Details
Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

NCT00235989

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Washington D.C., District of Columbia, United States
  • Atlanta, Georgia, United States
View all 17 locations
View Trial Details

Related conditions